Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
TITLE OF THE INVENTION
LYOPHILIZED ANTI-FUNGAL COMPOSITION
FIELD OF THE INVENTION
The invention is directed to caspofungin-containing pharmaceutical
compositions
useful for treating and/or preventing fungal infections.
BACKGROUND OF THE INVENTION
Caspofungin is a macrocyclic lipopeptide echinocandin whose structural formula
is disclosed in column 2, lines 32-52 of US 5952300. Caspofungin is also
described in
US 5378804, and methods for its preparation are described in US 5378804, US
5552521,
US 5952300 and US 6136783. Caspofungin is an inhibitor of the synthesis of 0-
(1,3)-D-glucan,
which is an integral part of the fungal cell wall. Caspofungin is useful as an
antibiotic, especially
as an antifungal agent or as an antiprotozoal agent. As an antifungal agent,
it is useful for the
control of both filamentous fungi and yeast. It is especially adaptable to be
employed for the
treatment of mycotic infections in mammals, especially those caused by Candida
species such as
C. albicans, C. tropicalis, C. krusei, C. glabrata and C. pseudotropicalis,
and Aspergillus
species such as A. fumigatus, A. flavus and A. niger. In particular, the
compound has been found
effective against putatively Amphotericin B- and Fluconazole-resistant Candida
isolates. The
compound is also useful for the treatment and/or prevention of Pneumocystis
carinii pneumonia
to which immune compromised patients, such as those suffering from AIDS, are
especially
susceptible.
Caspofungin is typically employed in a lyophilized composition that is
reconstituted for intravenous infusion. Preferred lyophilized caspofungin
compositions are
acetate-buffered products such as those described in US 5952300. Of particular
interest is the
lyophilized, acetate-buffered product containing caspofungin in the form of a
diacetate salt,
sucrose, mannitol, glacial acetic acid, and sodium hydroxide. Such a product
is available from
Merck & Co., Inc. under the trade name CANCIDAS in 35 mg, 50 mg, and 70 mg
doses.
CANCIDAS is indicated for empirical therapy for fungal infection in patients
with fever and
neutropenia, the treatment of Candidemia and certain other Candida infections,
the treatment of
esophageal Candidiasis, and the treatment of invasive Aspergillosis in
patients who are resistant
to or cannot tolerate other therapies.
Lyophilized, acetate-buffered, caspofungin products such as CANCIDAS are
characterized by good storage stability at low temperature (e.g., 2 C to 8 C)
under ambient
storage conditions. More particularly, the compositions can be stored at low
temperature (e.g.,
C) for many months with minimal formation of degradates. Nonetheless,
lyophilized
caspofungin-containing products with improved storage stability at low
temperatures and/or
satisfactory storage stability at higher temperatures is desirable. Improved
storage stability at
-1-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
about 5 C would provide for a longer shelf life thereby reducing the potential
for product loss.
Satisfactory storage stability at room temperature would eliminate the need
for refrigeration and
the special handling and extra costs associated therewith.
SUMMARY OF THE INVENTION
The present invention includes a lyophilized anti-fungal composition which
comprises:
(A) caspofungin, or a pharmaceutically acceptable salt thereof, in an
effective amount;
(B) one or more non-reducing sugars having a glass transition temperature
Tg(s) of at
least about 90 C; and
(C) an acetate buffer in an amount effective to provide a pH in a range of
from about 5
to about 7;
wherein:
the weight ratio of the one or more non-reducing sugars to caspofungin is in a
range of
from about 1.1:1 to about 10:1;
the composition has a moisture content of about 0.8 wt.% or less; and
the composition has a glass transition temperature Tg(c) of at least about 55
C.
The lyophilized anti-fungal composition of the present invention has good
chemical and storage stability at and below room temperature (i.e., at or
below about 30 C). The
composition typically has a stability exceeding that of known lyophilized
caspofungin-containing
compositions which employ sucrose and mannitol and have a Tg(c) in a range of
from about
40 C to about 45 C.
Embodiments, aspects and features of the present invention are either further
described in or will be apparent from the ensuing description, examples, and
appended claims.
DETAILED DESCRIPTION OF THE INVENTION
A first embodiment of the present invention (alternatively referred to herein
as
"Embodiment E 1") is a lyophilized composition as originally described (i.e.,
as described in the
Summary of the Invention) wherein the one or more non-reducing sugars is
selected from the
group consisting of trehalose, sucrose, raffinose, sorbitol and combinations
thereof. Suitable
combinations include any two of the sugars (e.g., trehalose and sucrose), any
three of the sugars
(e.g., trehalose, sucrose, and sorbitol), or all four of the sugars. In an
aspect of this embodiment,
the one or more non-reducing sugars is trehalose or a mixture of trehalose
with any one of
sucrose, raffinose and sorbitol. In a feature of this aspect, the non-reducing
sugar is trehalose or
a major amount of trehalose (i.e., trehalose is more than 50 wt.% of the
mixture) with any one of
sucrose, raffinose and sorbitol. In another feature of this aspect, the non-
reducing sugar is
-2-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
trehalose or is a combination of at least about 80 wt.% trehalose with any one
of sucrose,
raffinose and sorbitol.
A second embodiment of the present invention (Embodiment E2) is a lyophilized
composition as originally described wherein trehalose is the one or more non-
reducing sugars;
i.e., there is one non-reducing sugar present in the composition and that
sugar is trehalose. This
is alternatively and more simply expressed herein as "trehalose is the non-
reducing sugar".
A third embodiment of the present invention (Embodiment E3) is a lyophilized
composition as originally described or as set forth in either Embodiment E 1
or E2 wherein the
moisture content of the composition is about 0.5 wt.% or less.
A fourth embodiment of the present invention (Embodiment E4) is a lyophilized
composition as originally described or as set forth in either Embodiment E 1
or E2 wherein the
moisture content of the composition is about 0.3 wt.% or less.
A fifth embodiment of the present invention (Embodiment E5) is a lyophilized
composition as originally described or as set forth in any one of the
foregoing embodiments
wherein the glass transition temperature Tg(c) of the composition is at least
about 90 C.
A sixth embodiment of the present invention (Embodiment E6) is a lyophilized
composition as originally described or as set forth in any one of the
foregoing embodiments
wherein the glass transition temperature Tg(c) of the composition is in a
range of from about
90 C to about 125 C.
A seventh embodiment of the present invention (Embodiment E7) is a lyophilized
composition as originally described or as set forth in any one of the
foregoing embodiments
wherein the non-reducing sugar-to-caspofungin weight ratio of the composition
is in a range of
from about 2:1 to about 8:1.
An eighth embodiment of the present invention (Embodiment E8) is a lyophilized
composition as originally described or as set forth in any one of the
foregoing embodiments
wherein the non-reducing sugar-to-caspofungin weight ratio of the composition
is in a range of
from about 2:1 to about 6:1.
A ninth embodiment of the present invention (Embodiment E9) is a lyophilized
composition as originally described wherein trehalose is the non-reducing
sugar, the moisture
content of the composition is about 0.5 wt.% or less, the glass transition
temperature Tg(c) of the
composition is at least about 90 C, and the trehalose-to-caspofungin weight
ratio is in a range of
from about 2:1 to about 8:1. In an aspect of this embodiment, the glass
transition temperature
Tg(c) is in a range of from about 90 C to about 125 C.
A tenth embodiment of the present invention (Embodiment E10) is a lyophilized
composition as originally described wherein trehalose is the non-reducing
sugar, the moisture
content is about 0.3 wt.% or less, the glass transition temperature Tg(c) is
at least about 90 C,
-3-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
and the trehalose-to-caspofungin weight ratio is in a range of from about 2:1
to about 6:1. In an
aspect of this embodiment, the glass transition temperature Tg(c) is in a
range of from about
90 C to about 125 C.
An eleventh embodiment of the present invention (Embodiment E11) is a
lyophilized composition as originally described which is prepared by
lyophilizing an aqueous
solution comprising the caspofungin or its salt, the acetate buffer, and the
one or more non-
reducing sugars, wherein in the solution:
(A) the caspofungin or its salt has a concentration in a range of from about 5
mg/mL to about 200 mg/mL;
(B) the one or more non-reducing sugars has a concentration ratio on a mg/mL
basis with respect to caspofungin in a range of from about 2:1 to about 10:1;
and
(C) the acetate buffer has a concentration in a range of from about 12.5 mM to
about 200 mM.
Aspects of Embodiment E11 include the lyophilized composition as just
described
in Embodiment E11, wherein:
(Al) the one or more non-reducing sugars is a sugar selected from the group
consisting of trehalose, sucrose, raffinose, sorbitol and combinations
thereof.
(A2) trehalose is the non-reducing sugar.
(A3) the moisture content of the composition is about 0.5 wt.% or less.
(A4) the moisture content of the composition is about 0.3 wt.% or less.
(A5) the glass transition temperature Tg(c) of the composition is at least
about
90 C.
(A6) the glass transition temperature Tg(c) of the composition is in a range
of
from about 90 C to about 125 C.
(A7) the non-reducing sugar(s)-to-caspofungin weight ratio of the composition
is in a range of from about 2:1 to about 8:1.
(A8) the non-reducing sugar(s)-to-caspofungin weight ratio of the composition
is in a range of from about 2:1 to about 6:1.
(A9) trehalose is the non-reducing sugar, the moisture content of the
composition is about 0.5 wt.% or less, and the glass transition temperature
Tg(c) is at least about
90 C.
(A10) the composition is the same as set forth in A9, except that the moisture
content is about 0.3 wt.% or less.
-4-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
(A11) trehalose is the non-reducing sugar, the moisture content is of about
0.5
wt.% or less, the glass transition temperature Tg(c) is at least about 90 C,
and the trehalose-to-
caspofungin weight ratio is in a range of from about 2:1 to about 8:1.
(A12) trehalose is the non-reducing sugar, the moisture content is about 0.3
wt.%
or less, the glass transition temperature Tg(c) is at least about 90 C, and
the trehalose-to-
caspofungin weight ratio is in a range of from about 2:1 to about 6:1.
(A 13) the composition is the same as set forth in A11 except that the glass
transition temperature Tg(c) is in a range of from about 90 C to about 125 C.
(A14) the composition is the same as set forth in A12 except that the glass
transition temperature Tg(c) is in a range of from about 90 C to about 125 C.
A twelfth embodiment of the present invention (Embodiment E12) is a
lyophilized composition as set forth in Embodiment E11, wherein in the aqueous
solution from
which the lyophilized composition is prepared:
(A) the concentration of caspofungin or its salt is in a range of from about
30
mg/mL to about 50 mg/mL;
(B) the concentration ratio of the non-reducing sugar(s) to caspofungin is in
a
range of from about 4:1 to about 8:1; and
(C) the concentration of the acetate buffer is in a range of from about 20 mM
to about 60 mM.
A thirteenth embodiment of the present invention (Embodiment E13) is a
lyophilized composition as set forth in Embodiment E12, wherein trehalose is
the non-reducing
sugar, the moisture content of the composition is about 0.5 wt.% or less
(e.g., about 0.3 wt.% or
less), and the glass transition temperature Tg(c) of the composition is at
least about 90 C (e.g., in
a range of from about 90 C to about 125 C).
A fourteenth embodiment of the present invention (Embodiment E14) is a
lyophilized composition as set forth in Embodiment E 13, wherein in the
aqueous solution from
which the lyophilized composition is prepared:
(A) the concentration of caspofungin or its salt is in a range of from about
30
mg/mL to about 50 mg/mL;
(B) the concentration of trehalose is in a range of from about 180 mg/mL to
about 300 mg/mL (i.e., a trehalose to caspofungin concentration ratio of about
6:1); and
(C) the acetate buffer has a concentration in a range of from about 20 mM to
about 60 mM.
-5-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
A fifteenth embodiment of the present invention (Embodiment E 15) is a
lyophilized composition as originally described or as set forth in any of the
foregoing
embodiments or aspects or features thereof, wherein the composition is
substantially free of
reducing sugars. Reducing sugars can have a detrimental effect on the
stability of the lyophilized
compositions of the present invention (see below), and thus the compositions
preferably contain
little or no reducing sugar. The term "substantially free" in this context
means that no reducing
sugar is included as a component in the preparation of the lyophilized
composition and/or that
essentially no reducing sugar is present in the lyophilized composition.
An "effective amount" of caspofungin in the lyophilized composition is an
amount of caspofungin (on a free base basis) that upon reconstitution of the
lyophilized
composition can be employed (e.g., via parenteral administration) in a
therapeutically or
prophylactically effective amount to treat or prevent a fungal infection or
the like.
The term "pharmaceutically acceptable salt" refers to a salt which is not
biologically or otherwise undesirable (e.g., is neither toxic nor otherwise
deleterious to the
recipient thereof). The caspofungin salt can suitably be a mono-, di-, or tri-
acid salt. The salts
are suitably prepared by treating the free base with a suitable organic or
inorganic acid. Suitable
salts include acid addition salts such as the salts formed by treating the
free base with
hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, maleic
acid, critic acid, or
acetic acid.
The term "non-reducing sugar" refers to a carbohydrate that does not reduce
alkaline solutions of copper. Non-reducing sugars do not participate in the
Maillard reaction
with compounds containing primary amines (e.g., amino acids). The reducing or
non-reducing
nature of a sugar can be determined by the Fehling's test, which monitors the
reduction of Cu ++
to Cu+, with concomitant oxidation of the sugar. Non-reducing sugars do not
react in the
Fehling's test (i.e., they do not lead to the formation of cuprous oxide).
Exemplary non-reducing
sugars suitable for use in the present invention include trehalose, sucrose,
raffinose, and sorbitol.
A "reducing sugar" refers to a carbohydrate that does reduce alkaline
solutions of
copper (e.g., does react in the Fehling's test) and does participate in the
Maillard reaction with
compounds containing primary amines.
The glass transition temperatures referred to herein (e.g., Tg(s) and Tg(c) )
are the
transition temperatures determined using differential scanning calorimetry
(DSC). DSC
measures the change in heat capacity between the glassy and rubbery states and
is typically
indicated by a change in baseline in a DSC thermogram.
-6-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
The glass transition temperature Tg(c) of the lyophilized composition of the
present invention will typically decrease as the amount of moisture in the
composition increases.
Furthermore, even in cases where the lyophilized composition can tolerate a
relatively large
amount of moisture and still have a suitable Tg(c), the presence of a
relatively large amount of
moisture is often deleterious for other reasons. For example, the moisture can
be a source of
chemical degradation of the active ingredient by, for example, hydrolysis.
Accordingly, the
lyophilized composition of the present invention is characterized by having a
low moisture
content. More particularly, for the purposes of this invention, if (i) the
amount of moisture in the
composition is about 0.8 wt.% or less and (ii) the Tg(c) of the lyophilized
composition is at least
about 55 C, then the composition is deemed to have a low moisture content and
to be a
composition of the present invention. Both (i) and (ii) must be satisfied for
the composition to be
a composition of the present invention. Thus, if a lyophilized composition has
a moisture
content of less than about 0.8 wt.% but its Tg(c) is below about 55 C, the
composition is not a
composition of the present invention. Furthermore, if a lyophilized
composition has a Tg(c)
above about 55 C but its moisture content is more than 0.8 wt.%, the
composition is not
considered as having a low moisture content and is not a composition of the
present invention.
The lyophilized composition of the invention typically has a moisture content
of less than about
0.5 wt.% and a Tg(c) above about 55 C, and preferably has a moisture content
of less than about
0.5 wt.% and a Tg(c) above about 90 C.
Tg(s), the glass transition temperature of the one or more non-reducing sugars
employed in the lyophilized anti-fungal composition of the invention is the
glass transition
temperature of the sugar(s) after lyophilization of the non-reducing sugar(s)
in the same manner
as the anti-fungal composition is lyophilized, wherein the lyophilization
generates an amorphous
form of the non-reducing sugar(s). The Tg(s) value of the one or more non-
reducing sugars used
in the present invention is at least about 90 C and is typically in a range of
from about 90 C to
about 125 C.
When more than one non-reducing sugar is employed, it is the Tg(s) value of
the
the sugars together in a mixture (after lyophilization) that must be at least
about 90 C. A non-
reducing sugar whose glass transition temperature is below 90 C can be
included in the
composition, provided that the Tg(s) of all of the non-reducing sugars
together (after
lyophilization) is about 90 C or higher. Typically, however, each of the non-
reducing sugars
employed in the lyophilized composition has an individual glass transition
temperature of at least
about 90 C.
-7-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
The moisture content of the lyophilized composition is determined by the Karl
Fisher coulometry method, wherein the residual water is extracted from the
composition using
methanol or some other suitable extraction agent. The water present in the
methanol or other
reagent is then titrated with a Karl Fischer solution that reacts with the
water to form colorless
hydrogen iodide. When all of the water has been consumed, free iodine, which
has color,
appears, thereby indicating an end point before which the conductivity of the
solution will have
changed. The moisture content can then be determined from a measurement of the
amount of HI
formed during the titration.
The term "about", when modifying the quantity of a substance or composition,
or
the value of a physical property (e.g., moisture content, Tg(c), Tg(s), or the
like) of a substance or
composition, or the value of a parameter characterizing a process, or the like
refers to variation in
the numerical quantity that can occur, for example, through typical measuring
and handling
procedures employed in the preparation, characterization, and use of the
lyophilized
compositions of the invention; for making concentrates or use solutions in the
real world;
through inadvertent error in these procedures; through differences in the
manufacture, source, or
purity of the ingredients employed to make or use the compositions or carry
out the procedures;
and the like. In one embodiment, the term "about" means the reported numerical
value + 10%
thereof. In an aspect of this embodiment, the term "about" means the reported
numerical value
+ 5% thereof.
An "effective amount" of an acetate buffer is an amount of the buffer that can
provide, with suitable adjustment as needed by addition of base (e.g., a
hydroxide such as
NaOH), a pH in the indicated range in the aqueous solution from which the
lyophilized
composition of the invention is prepared (i.e., in the pre-lyophilization
solution).
Unless expressly stated to the contrary, a reference to pH herein means the pH
at
ambient temperature; i.e., at a temperature in a range of from about 20 C to
about 25 C.
The lyophilized compositions of the present invention are not limited to the
active
ingredient (i.e., caspofungin) or its salt, the acetate buffer and the non-
reducing sugar(s). The
composition can include other components such as (i) a minor amount of a
bulking agent (e.g., a
polyol) in addition to the non-reducing sugar(s) or (ii) an anti-oxidant such
as BHT, BHA, alpha-
tocopherol, or ascorbic acid. If employed, the bulking agent is typically
present in an amount of
less than about 10 wt.%, preferably less than about 5 wt.%, with respect to
the non-reducing
sugar(s).
-8-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
The present invention also includes a process for preparing a lyophilized
anti-fungal composition with a moisture content of less than about 0.8 wt.%
(alternatively
referred to herein as "Process P 1"), which comprises
(A) preparing an aqueous solution with a pH in a range of from about 5 to
about 7 and comprising an effective amount of caspofungin or a
pharmaceutically acceptable salt
thereof, one or more non-reducing sugars having a glass transition temperature
Tg(s) of at least
about 90 C, and an acetate buffer, wherein the concentration ratio, on a
weight per unit volume
basis, of the one or more non-reducing sugars to caspofungin is in a range of
from about 1.1:1 to
about 10:1; and
(B) freeze-drying the aqueous solution to provide the lyophilized anti-fungal
composition.
A first embodiment of Process P 1(alternatively referred to herein as
"Embodiment P1-E1") is the process as originally described, wherein Step A
further comprises:
(al) dissolving the one or more non-reducing sugars in water;
(a2) adding acetic acid and then adjusting the pH to be in a range of from
about
4.5 to about 5.5 by addition of base;
(a3) adding caspofungin or its salt and adjusting the pH to a value in a range
of
from about 5 to about 7 (e.g., about 6) by addition of more base; and
(a4) optionally filtering the resulting aqueous solution.
When more than one non-reducing sugar is employed in sub-step al of Step A in
the Process P1, the sugars can be dissolved in any convenient way. For
example, the sugars can
be mixed together and the dry mixture dissolved in water to provide the
solution employed in
sub-step a2, or alternatively the sugars can be dissolved individually in
separate portions of water
to provide separate aqueous sub-solutions and the separate sub-solutions added
together and
optionally diluted if necessary to give the solution employed in sub-step a2,
or alternatively the
sugars can be added separately to the same portion of water and dissolved
therein and optionally
diluted if necessary to provide the solution employed in sub-step a2. When
added separately, the
individual non-reducing sugars can be added concurrently or at different times
in any order.
A second embodiment of Process P 1(Embodiment P 1-E2) is the process as
originally described or as set forth in Embodiment P 1-E 1, wherein in the
aqueous solution
resulting from Step A the caspofungin or its salt has a concentration in a
range of from about 5
mg/mL to about 200 mg/mL, and the concentration ratio of the non-reducing
sugar(s) to
caspofungin is in a range of from about 2:1 to about 10:1.
-9-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
A third embodiment of Process Pl (Embodiment P1-E3) is the process as
originally described or as set forth in Embodiment P1-E1, wherein in the
aqueous solution
resulting from Step A the caspofungin or its salt has a concentration in a
range of from about 30
mg/mL to about 50 mg/mL, and the concentration ratio of the non-reducing
sugar(s) to
caspofungin is in a range of from about 4:1 to about 8:1.
A fourth embodiment of Process P 1(Embodiment P 1-E4) is the process as
originally described or as set forth in any one of Embodiments P 1-E 1 to P 1-
E3, wherein the one
or more non-reducing sugars is selected from the group consisting of
trehalose, sucrose,
raffinose, sorbitol and mixtures thereof.
A fifth embodiment of Process P1 (Embodiment P1-E5) is the process as
originally described or as set forth in any one of Embodiments P 1-E 1 to P 1-
E3, wherein
trehalose is the non-reducing sugar.
A sixth embodiment of Process P 1(Embodiment P 1-E6) is the process as
originally described or as set forth in any one of the foregoing embodiments
of P1, wherein the
moisture content of the lyophilized composition is about 0.5 wt.% or less.
A seventh embodiment of Process P 1 (Embodiment P 1-E7) is the process as
originally described or as set forth in any one of the foregoing embodiments
of P1, wherein the
moisture content of the lyophilized composition is about 0.3 wt.% or less.
An eighth embodiment of Process P 1(Embodiment P 1-E8) is the process as
originally described or as set forth in any one of the foregoing embodiments
of P1, wherein the
lyophilized composition has a glass transition temperature Tg(c) of at least
about 90 C (e.g., in a
range of from about 90 C to about 125 C).
The present invention also includes a lyophilized anti-fungal composition
prepared by the process P 1 as originally described or as set forth in any one
of the foregoing
embodiments of P I.
The freeze-drying (i.e, lyophilizing) of the aqueous solution resulting from
Step A
of Process P 1 involves first cooling the solution to a temperature at or
below the freezing point of
the solution (i.e., below its glass transition temperature if the solution
forms a glass upon cooling
and below its eutectic point if the frozen solution is crystalline). The
frozen solution is then
typically subjected to a primary drying step in which the temperature is
gradually raised under
vacuum in a drying chamber to remove most of the water, and then to a
secondary drying step
typically at a higher temperature than employed in the primary drying step to
remove the residual
moisture in the lyophilized composition. The freeze drying step typically
requires 48 hours or
more to complete. The lyophilized composition is then appropriately sealed and
stored (e.g., in
-10-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
stoppered vials) for later use. Tang et al., Pharmaceutical Research 2004,
vol. 21, pp. 191-200
describes the scientific principles pertaining to freeze drying and guidelines
for designing
suitable freeze drying processes. Further description of freeze drying is
found in Remington -
The Science and Practice of Pharmacy, 2006, 21st edition, Lippincott Williams
& Wilkins, pp.
828-831.
The lyophilized compositions of the present invention are characterized by
having
good chemical and storage stability at temperatures up to and including room
temperature.
Caspofungin has two main degradation products. The first is formed via
hydrolysis in the pre-
lyophilization solution, and the second is formed in the lyophilized
composition as a result of
intramolecular rearrangement. It has been found that the lyophilized
compositions of the present
invention exhibit reduced growth of the second degradate during storage
compared to analogous
known compositions with the same or similar moisture content.
The lyophilized compositions of the present invention are reconstituted for
use in
preventing or treating fungal infections. The present invention accordingly
includes a method of
preparing an anti-fungal liquid formulation for parenteral administration
(alternatively referred to
herein as "Method M1 "), which comprises reconstituting (i) the lyophilized
anti-fungal
composition as originally described in the Summary of the Invention or as set
forth in any one of
Embodiments El to E15 or in any aspects or features thereof or (ii) the
lyophilized anti-fungal
composition resulting from Process P1 as originally described or as set forth
in any one
Embodiments P 1-E 1 to P 1-E8 with a parenterally acceptable solvent to form
an anti-fungal
solution concentrate and then mixing the concentrate with a diluent comprising
water to provide
the formulation.
A first embodiment of Method M 1(alternatively referred to herein as
"Embodiment M 1-E 1") is the Method M 1 as originally described, wherein the
parenterally
acceptable solvent comprises water.
A second embodiment of Method M 1(Embodiment M 1-E2) is the Method M 1 as
originally described, wherein the parenterally acceptable solvent is selected
from the group
consisting of 0.9% Sodium Chloride Injection, Sterile Water for Injection,
Bacteriostatic Water
for Injection with methylparaben and propylparaben, and Bacteriostatic Water
for Injection with
0.9% benzyl alcohol.
A third embodiment of Method M 1(Embodiment M 1-E3) is the Method M 1 as
originally described or as set forth in either Embodiment M 1-E 1 or M 1-E2,
wherein the diluent is
0.9%, 0.45% or 0.225% Sodium Chloride Injection or Lactated Ringer's
Injection.
-11-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
A fourth embodiment of Method M 1(Embodiment M 1-E4) is the Method M 1 as
originally described or as set forth in any of the foregoing embodiments of
M1, wherein the
concentrate contains from about 5 mg/mL to about 8 mg/mL of caspofungin, and
the liquid
formulation resulting from dilution of the concentrate contains from about 0.2
mg/mL to about
0.5 mg/mL of caspofungin.
The present invention further includes an anti-fungal liquid dosage
formulation
for parenteral administration prepared by the Method M1 as originally
described or as set forth in
any one of the foregoing embodiments of M 1.
The present invention still further includes a method for the treatment or
prophylaxis of a fungal infection which comprises parenterally administering
to a subject in need
thereof an anti-fungal liquid formulation prepared by the Method M1 as
originally described or
as described in any one of the foregoing embodiments of Method Ml.
The present invention also includes an anti-fungal liquid dosage formulation
prepared by the Method Ml as originally described or as described in any one
of the foregoing
embodiments of Method Ml (i) for use in, (ii) for use as a medicament for, or
(iii) for use in the
preparation of a medicament for the treatment or prophylaxis of a fungal
infection.
The present invention still further includes a kit comprising a first
container
having the (i) the lyophilized anti-fungal composition as originally described
in the Summary of
the Invention or as set forth in any one of Embodiments E 1 to E 15 or in any
aspects or features
thereof or (ii) the lyophilized anti-fungal composition resulting from Process
P 1 as originally
described or as set forth in any one Embodiments P 1-E 1 to P 1-E8 and a
second container having
a parenterally acceptable solvent for reconstitution thereof. The kit can
include other
components such as vials, stirrers, lids, and instructions for reconstitution,
mixing, storage and/or
use.
As used herein, parenteral administration includes but is not limited to
administration of the formulation by subcutaneous injection or via intravenous
or intramuscular
injection or infusion techniques. The anti-fungal liquid dosage formulation of
the invention is
typically administered by intravenous infusion.
A "parenterally acceptable solvent" is a solvent which is not biologically or
otherwise undesirable (e.g., does not typically produce an unintended allergic
reaction or other
adverse event) during or following parenteral administration.
The regimens utilizing a dosage formulation of the present invention for
parenteral administration are selected in accordance with a variety of factors
including type of
species being administered to (i.e., animal, preferably mammal, and most
preferably human); the
-12-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
age, weight, sex and medical condition of the patient; the severity of the
condition to be treated;
and the renal and hepatic function of the patient. A veterinarian or physician
of ordinary skill can
readily determine and prescribe a dose suitable for preventing or treating the
anti-fungal
infection. Further description on the dosage and administration of caspofungin
to humans is
provided in the entry for Intravenous Infusion CANCIDAS in the 2007 edition of
the Physician's
Desk Reference.
The following examples serve only to illustrate the invention and its
practice. The
examples are not to be construed as limitations on the scope or spirit of the
invention.
The high performance liquid chromatography (HPLC) analysis referred to in
Example 3 below was conducted using: column = Waters Symmetry C 18 (5 m
particle size,
250 x 4.6 mm); column temperature = ambient; detection = UV absorbance at 220
nm;
autosampler = temperature controlled at approximately 5 C; diluent =
acetonitrile; sodium
acetate buffer: 1:4; mobile phase A: 0.1% perchloric acid, 0.075% NaCI; mobile
phase B:
acetonitrile; program:
Time (min) %A %B Flow rate (mL/min)
0 65.5 34.5 1.0
14.5 65.5 34.5 1.0
35 50 50 1.0
45 35 65 1.0
50 20 80 1.0
52 20 80 1.0
53 65.5 34.5 1.0
53.5 65.5 34.5 1.0
54 65.5 34.5 1.5
63 65.5 34.5 1.5
63.5 65.5 34.5 1.0
66 65.5 34.5 1.0
The retention time for caspofungin is 20.3 minutes.
EXAMPLE 1
Preparation of Lyophilized Caspofun-gin Diacetate Composition
Trehalose (11.99 g) was dissolved in 30 mL of water, followed by the addition
of
glacial acetic acid (75 L; density = 1.049 g/mL) to provide a solution with a
pH of about 3. The
solution pH was adjusted to about 5.1 by the addition of 1N NaOH, after which
caspofungin
-13-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
diacetate (2.23 g = 2.00 g of free base) was added and the mixture gently
stirred and shaken to
dissolve the caspofungin without foaming. The pH of the solution was then
adjusted to 6.0 by
addition of 1N NaOH. Water was then added to bring the volume of the solution
to 50 mL and
the resulting solution was filtered through 0.22 gm filter units. This pre-
lyophilization solution
had the following composition:
caspofungin diacetate (free base equivalent) = 40.0 mg/mL
trehalose = 240.0 mg/mL
glacial acetic acid = 1.5 mg/mL
NaOH = sufficient to provide pH = 6.0
water for injection = q.s. 1.00 mL
Aliquots of 0.5 mL of the solution were then placed in 3 mL lyophilization
vials
and the vials partially stoppered with 13 mm bromobutyl lyo stoppers (4405/50
gray) (available
from West Pharmaceutical Services) which had been dried overnight at 110 C.
The vials were then lyophilized using a VirTis Genesis lyophilizer. The vials
were placed in lyophilization trays and the trays loaded onto the lyophilizer
shelves. The cycle of
steps employed to obtain lyophilized compositions was as follows:
L o hilization Cycle Step
1. Cool to - 40 C 0.2 C/min 9. Hold at -10 C for 400 min
2. Hold at - 40 C for 120 min 10. Ramp to -5 C 0.1 C/min
3. Apply 80 mTorr vacuum 11. Hold at -5 C for 400 min
4. Ramp to -20 C 0.1 C/min 12. Ramp to +15 C 0.1 C/min
5. Hold at -20 C for 3000 min 13. Hold at +15 C for 720 min
6. Ramp to -15 C 0.1 C/min 14. Ramp to +25 C 1 C/min
7. Hold at -15 C for 900 min 15. Hold at +25 C for 240 min
8. Ramp to -10 C 0.1 C/min
The lyophilized compositions were stored in the lyophilized state at 5 C, 25 C
and 30 C, and then tested after 1, 2, 4 and 6 months for stability in the
manner described in
Example 3.
Glass transition temperatures. The Tg(c) of the lyophilized composition was
determined using a DSC Q2000 (TA Instruments) under a stream of nitrogen gas
at 50
mL/minute as the purge gas. Several samples of the lyophilized composition
(each about 5 mg)
were prepared in a nitrogen purged glove box, and each was loaded into an
aluminum DSC pan
and hermetically sealed. The pans along with an empty pan as control were run
in the DSC. The
-14-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
pans were first equilibrated at 25 C, then modulated at + 0.5 C every 60
seconds, and then the
temperature was raised at a rate of 2.5 C per minute to a final temperature of
140 C. The
samples was determined to have a Tg(c) of 97 + 2 C.
Several samples of trehalose were lyophilized in the same manner as set forth
above for the caspofungin diacetate composition. The glass transition
temperature Tg(s) of each
of the lyophilized trehalose samples was determined using the instrument and
procedure
employed to determine Tg(c) described in the preceding paragraph. The average
Tg(s) of the
samples was 118 + 2 C.
Moisture content. The moisture content of the lyophilized composition was
determined via Karl Fischer coulometry (extraction agent - methanol:formamide
in 1:1 ratio by
volume) to be 0.3 0.2 wt.% (n=3).
EXAMPLE 2
Preparation of Lyophilized Compositions
The lyophilized compositions 2-1 to 2-101isted in Table 2 below were prepared
in
a manner similar to that set forth for the lyophilized composition of Example
1, except that the
secondary drying in the lyophilization cycle was performed at 15 C instead of
25 C: The Tg(c)
and moisture content of the lyophilized compositions were determined in the
manner described
in Example 1. Table 2 also lists the corresponding values for the composition
prepared in
Example 1 and for the marketed product CANCIDAS.
Table 2 - L o hilized Com ositions1,2
Example CPFGN free SUG SUG:CPFGN Tg(c) Moisture
No. base (mg/mL) weight ratio ( C) content (wt.%)
mg/mL
2-1 40.0 MAN = 20.0 1.25 42 -0.5
SUC = 30.0
2-2 40.0 MAN = 20.0 1.25 40-45 0.15
SUC = 30.0
2-3 37.8 MAN = 20.0 1.32 n.m. 0.57
SUC = 30.0
2-4 37.8 TRE = 50.0 1.32 n.m. 0.50
2-5 37.8 TRE = 30.0 1.32 n.m. 0.79
LAC = 20.0
-15-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
2-6 37.8 TRE = 20.0 1.32 n.m. 0.62
LAC = 30.0
2-7 37.8 LAC = 50.0 1.32 n.m. 0.61
2-8 40.0 TRE = 20.0 0.5 n.m.3 0.56
2-9 40.0 TRE = 40.0 1.0 n.m.3 0.52
2-10 40.0 TRE = 80.0 2.0 93 0.46
1 40.0 TRE = 240.0 6.0 97 0.3
MP 42.0 MAN = 20.0 1.20 40-45 -0.5
SUC = 30.0
1. CPFGN = caspofungin; LAC = lactose; MAN = mannitol; n.m. = not measured; MP
= marketed product CANCIDAS; SUC = sucrose; SUG = sugar(s); TRE = trehalose.
2. The pre-lyophilization solution for each of these compositions had a pH of
6.0,
contained 1.5 mg/mL of glacial acetic acid, NaOH = q.s. pH 6, and water for
injection = q.s. 1 mL.
3. The Tg(c) values for these samples were not determined, but it is believed
these
compositions have Tg(c)'s of about 90.
Immediately following preparation, each of the the lyophilized compositions
was
tested for stability in the manner described in Example 3. The lyophilized
compositions in Table
2 differ in their moisture content. As noted earlier, moisture can be a source
of chemical
degradation of caspofungin by, for example, hydrolysis. However, the moisture
content in all of
these compositions is believed too low to be a significant factor in the
interpretation of the
stability results reported in Example 3; i.e., the trends in stability
observed in Example 3 are
primarily due to the choice and relative amounts of the sugars employed in the
compositions and
not to any differences in moisture content.
EXAMPLE 3
Stability Tests
A. The stabilities of compositions 2-3, 2-4, 2-5, 2-6 and 2-7 were compared by
placing samples of each composition at each of several temperature stations
and monitoring their
stability after 2 weeks, 4 weeks and 8 weeks. Three vials of each of these
compositions were
placed for each time point at each of the following stations: 5 C, 25 C at 65%
relative humidity
(RH) and 40 C at 75% RH. (Note: RH is not considered to be a critical
parameter since the
lyophilized compositions are in glass vials sealed with stoppers and caps so
that no moisture
-16-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
exchange should occur.) The sample vials were tested for stability after the
first 2 weeks by
determining the amount of caspofungin in the samples using HPLC. Examples 2-3,
2-4 and 2-7
were then selected for testing to and comparison at 4 weeks, and subsequently
Examples 2-3 and
2-4 were selected for testing to and comparison at 8 weeks. The selective
results obtained at 8
weeks were consistent with the 2-week and 4-week results, which are shown in
Table 3-A below.
Table 3-A
Ex. No. Temp Timepoint CPFGN
( C) (wks) assay (%)
2-3 40 2 54.2
2-3 40 4 39.0
2-4 40 2 94.5
2-4 40 4 90.5
2-5 40 2 83.3
2-6 40 2 80.5
2-7 40 2 78.2
2-7 40 4 57.0
The data in Table 3-A demonstrate that the lyophilized composition of Example
2-4 is the most stable of the compositions tested in terms of loss of
caspofungin. The data also
indicate that formulations containing trehalose (2-4,'2-5, 2-6) were more
stable than the non-
trehalose-containing formulations (2-3 and 2-7). While not wishing to be bound
by any
particular theory, it is believed that the lower stability observed for the
lactose-containing
formulations is due to the Maillard reaction that occurs between reducing
sugars, such as lactose,
and molecules, such as caspofungin, containing a nucleophilic amino group.
B. The stabilities of the compositions 2-1, 2-8, 2-9 and 2-10 were compared by
placing samples of each composition at each of several temperature stations
and monitoring their
stability at 4-week intervals for 8 weeks. More particularly, 3 vials of each
of these compositions
were placed for each time point at each of the following stations: 5 C, 25 C
at 65% RH, 30 C at
60% RH, and 40 C at 75% RH. The sample vials were tested for stability by
determining the
amount of caspofungin and the casponfungin degradate that forms in the
lyophilized cake over
time (determined as wt.% of caspofungin) in the samples using HPLC. The
results are shown in
Table 3-B below.
-17-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
Table 3-B
Ex. No. Temp Timepoint CPFGN assay Degradate
( C) (wks) (%) (wt.% of active)
2-1 30 8* 75.1 3.2
40 8* 21.5# 0.5#
2-8 30 8* 81.0 2.3
40 8* 65.3 4.3
2-9 30 8* 83.9 1.8
40 8* 75.7 3.9
2-10 30 8* 83.5 1.6
40 8* 79.9 3.2
* The stoppers were not properly dried and the moisture content
was measured to be -2.0% after 1 month
# No mass balance
The results in Table 3-B show that the stability of the trehalose-containing
lyophilized
compositions is superior to that of the lyophilized composition containing no
trehalose (i.e., Ex.
No. 2-1 containing sucrose and mannitol) and that the stability of the
trehalose-containing
compositions increases with increasing concentration of trehalose. More
particularly, as the ratio
of trehalose to caspofungin free base increased from 0.5 to 1.0 to 2.0, the
generation of degradate
decreased from 2.3% to 1.8% to 1.6%, respectively, at 30 C after 8 weeks. A
similar trend was
observed at 40 C.
C. The stabilities of the compositions of Examples 1 and 2-2 were compared by
placing samples of each composition at each of several temperature stations
and monitoring their
stability after 4-week, 8-week, 16-week, 24-week and 72-week (at 30 C for only
Example 1
formulation) time points. More particularly, 3 vials of each of the two
compositions were placed
for each time point at each of the following stations: 5 C, 25 C at 65% RH, 30
C at 60%RH,
and 40 C at 75% RH. The sample vials were tested for stability for up to 24
weeks by
determining the amount of caspofungin and the casponfungin degradate that
forms in the
lyophilized composition over time (calculated as wt.% of active) in the
samples using HPLC.
The results are shown in Table 3-C below. Table 3-C also contains historical
data based on two
different lots of the marketed product MP (CANCIDASTM), wherein each lot
included
lyophilized product containing 35 mg, 50 mg, and 75 mg of caspofungin.
-18-
CA 02692053 2009-12-18
WO 2009/002481 PCT/US2008/007810
Table 3-C
Ex. No. Tg(c)1 Temp Timepoint CPFGN assay Key Degradate
( C) ( C) (wks) (%) (% of CPFGN)
MP 40-45 30 24 2.1
52 89.24 4.7
2-2 40-45 30 24 101.32 0.8
2-2 40 16 77.0 6.0
24 n.a.3 n.a.
1 97 30 8 98.5 0.7
16 97.9 0.8
24 95.5 1.2
93.4 1.7
72
1 40 24 88.0 1.9
1. Tg(c) values are from Table 2.
2. Although >100%, the value was within fill and analytical
variances.
3. n.a. = not assayed, due to severe browning of the sample
which accordingly was not deemed fit for analysis.
The results in Table 3-C show that Example 1 exhibits a long-term thermal
stability superior to that observed for the marketed product and for Example 2-
2. More
particularly, the level of degradate generated in Example 1 after 24 weeks and
72 weeks at 30 C
is markedly less than the degradate levels seen in MP at 24 weeks and 52
weeks, respectively.
Example 1 has a degradate level higher than that of Example 2-2 at 30 C, but
Example 1 is much
more stable than 2-2 at 40 C.
While the foregoing specification teaches the principles of the present
invention,
with examples provided for the purpose of illustration, the practice of the
invention encompasses
all of the usual variations, adaptations and/or modifications that come within
the scope of the
following claims.
-19-
